Placebo + ALN-APP

Phase 2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cerebral Amyloid Angiopathy

Conditions

Cerebral Amyloid Angiopathy

Trial Timeline

May 17, 2024 → Dec 14, 2029

NCT ID

NCT06393712

About Placebo + ALN-APP

Placebo + ALN-APP is a phase 2 stage product being developed by Alnylam Pharmaceuticals for Cerebral Amyloid Angiopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06393712. Target conditions include Cerebral Amyloid Angiopathy.

What happened to similar drugs?

5 of 17 similar drugs in Cerebral Amyloid Angiopathy were approved

Approved (5) Terminated (1) Active (12)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅RosuvastatinAstraZenecaApproved

✅clopidogrel (SR25990C)SanofiApproved

✅PiracetamUCBApproved

✅Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.Brain BiotechApproved

🔄Oral Glycopyrrolate LiquidShionogiPhase 3

🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06393712	Phase 2	Recruiting	May 17, 2024	Dec 14, 2029	Cerebral Amyloid Angiopathy

Competing Products

20 competing products in Cerebral Amyloid Angiopathy

See all competitors

Product	Company	Stage	Hype Score
mouse nerve growth factor	Sun Pharmaceutical	Approved	39
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Oral Glycopyrrolate Liquid	Shionogi	Phase 3	40
recombinant human erythropoietin alfa + 0.9% NaCl	Johnson & Johnson	Phase 2/3	38
UDI-001	Rohto Pharmaceutical	Phase 1/2	32
NXY-059	AstraZeneca	Phase 3	40
NXY-059	AstraZeneca	Phase 2	35
Rosuvastatin	AstraZeneca	Approved	39
NXY-059	AstraZeneca	Phase 3	40
Comparator: Placebo + Comparator: MK0724	Merck	Phase 2	27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg	Merck	Phase 2	35
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
Ponezumab	Pfizer	Phase 2	35
PF-05230907	Pfizer	Phase 1	21
Azithromycin + Pyrimethamine + Leucovorin calcium	Pfizer	Phase 1	29
clopidogrel (SR25990C)	Sanofi	Approved	43
Intrarectal quinine	Sanofi	Phase 3	36
Piracetam	UCB	Approved	35
CN-105	Tiantan Bio	Phase 2	28